Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Dermira
Biotech
Lilly’s $1B bet yields 'compelling' data on Dupixent rival
Analysts at Jefferies called the data compelling, although a hoped-for point of differentiation over the blockbuster incumbent has weakened.
Nick Paul Taylor
Mar 28, 2022 7:40am
Evommune snags $83M for "Tylenol for itch," three other programs
Sep 9, 2021 7:30am
Aslan hires Kobayashi to add IL-13 clinical trial expertise
Aug 3, 2020 8:56am
Pfizer’s Dupixent rival makes the grade in phase 3—again
Mar 18, 2020 8:44pm
Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout
Jan 10, 2020 8:20am
Pfizer's JAK inhibitor hits the mark in another eczema trial
Sep 27, 2019 11:11am